OncoMed Pharmaceuticals, Inc.

Company Listings from SPi: OncoMed Pharmaceuticals, Inc.

You are here: Home >> SPi Company Listings >> OncoMed Pharmaceuticals, Inc.

 

OncoMed Pharmaceuticals, Inc.

Website:
http://

Search for other references to "oncomed" on SPi News

Latest OncoMed Pharmaceuticals, Inc. News

OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discov...... 11:00 GMT Friday 15th March 2019

OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results REDWOOD CITY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and develo...... 21:00 GMT Thursday 7th March 2019

Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals  To be effected by an all-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019Deal broadens asset and shareholder base and extends...... 13:10 GMT Wednesday 5th December 2018

OncoMed Announces Early Clinical Data for anti-TIGIT Antibody REDWOOD CITY, Calif. and WASHINGTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discove...... 13:00 GMT Friday 9th November 2018

OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights  -Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation of...... 20:05 GMT Thursday 1st November 2018

OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and develop...... 13:00 GMT Monday 22nd October 2018

OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer REDWOOD CITY, Calif., Oct. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and develop...... 11:30 GMT Saturday 20th October 2018

OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and develop...... 13:00 GMT Tuesday 9th October 2018

OncoMed to Present at the Cantor Global Healthcare Conference REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and develo...... 21:00 GMT Monday 24th September 2018

OncoMed Announces Publication of Phase 1a Data of Navicixizumab REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and develo...... 13:00 GMT Monday 24th September 2018

Buy OncoMed Pharmaceuticals, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us